| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 57894-0100-60 | 57894-0100 | NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE | AKEEGA | 500.0 mg/1, 100.0 mg/1 | Chemotherapy | Androgen Receptor Inhibitor, Enzyme Inhibitor | CYP17, PARP | Oral | Aug 11, 2023 | In Use | |
| 57894-0514-01 | 57894-0514 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | RYBREVANT FASPRO | 2240.0 mg/14mL, 28000.0 mg/14mL | Immunotherapy | Bispecific Antibody | EGFR, MET | Subcutaneous | Dec 17, 2025 | In Use | |
| 57894-0515-01 | 57894-0515 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | Rybrevant Faspro | 2400.0 mg/15mL, 30000.0 mg/15mL | Immunotherapy | Bispecific Antibody | EGFR, MET | Subcutaneous | Feb 13, 2026 | In Use | |
| 52652-2001-06 | 52652-2001 | Methotrexate | Xatmep | 2.5 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug 13, 2018 | In Use | |
| 58118-7500-08 | 58118-7500 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 13, 2018 | In Use | |
| 59353-0004-10 | 59353-0004 | Epoetin alfa-epbx | RETACRIT | 4000.0 [iU]/mL, 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
| 59572-0984-01 | 59572-0984 | Romidepsin | Istodax | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jan 4, 2010 | In Use | ||
| 59651-0194-01 | 59651-0194 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Oct 30, 2020 | In Use | |
| 59651-0414-01 | 59651-0414 | HYDROCORTISONE | HYDROCORTISONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 17, 2023 | In Use | |
| 59651-0543-15 | 59651-0543 | DASATINIB | DASATINIB | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 59676-0600-12 | 59676-0600 | Apalutamide | ERLEADA | 60.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Feb 14, 2018 | In Use | |
| 59923-0714-02 | 59923-0714 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Mar 1, 2019 | In Use | |
| 64980-0334-14 | 64980-0334 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 17, 2017 | In Use | |
| 63629-4788-05 | 63629-4788 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 9, 2017 | In Use | ||
| 61919-0149-21 | 61919-0149 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 1, 2014 | In Use | |
| 63187-0080-18 | 63187-0080 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Mar 25, 2022 | In Use | ||
| 64380-0763-04 | 64380-0763 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 9, 2016 | In Use | |
| 64679-0726-01 | 64679-0726 | ondansetron hydrochloride | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 27, 2006 | In Use | |
| 64679-0794-01 | 64679-0794 | imatinib mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 17, 2019 | In Use | |
| 50090-0097-07 | 50090-0097 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 28, 2014 | In Use | |
| 42291-0505-01 | 42291-0505 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct 5, 2020 | In Use | |
| 70518-3818-00 | 70518-3818 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug 3, 2023 | In Use | ||
| 65219-0568-00 | 65219-0568 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jan 15, 2023 | In Use | |
| 66993-0236-30 | 66993-0236 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 50268-0621-15 | 50268-0621 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 5, 2016 | In Use |
Found 12250 results — Export these results
Home